Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 15/20 | 0.59 |
| ▸ | CA9 | Q16790 | 14/20 | 0.59 |
| ▸ | ELANE | P08246 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 5/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8245848 | 0.86 | CA12 (0.46) | CA12CA9ELANEKMT2ATDP1 | |
| SCHEMBL12601260 | 0.81 | CA12 (0.56) | CA12CA9ELANEKMT2ATDP1 | |
| SCHEMBL13632922 | 0.81 | CA12 (0.56) | CA12CA9ELANEKMT2ATDP1 | |
| SCHEMBL26232554 | 0.80 | CA12 (0.68) | CA12CA9ELANEKMT2ACA2 | |
| SCHEMBL12600751 | 0.78 | CA12 (0.52) | CA12CA9ELANEKMT2ATDP1 | |
| SCHEMBL18026643 | 0.77 | CA12 (0.68) | CA12CA9ELANEKMT2ATDP1 | |
| SCHEMBL8970514 | 0.75 | CA12 (0.65) | CA12CA9ELANECA2CA1 | |
| SCHEMBL8865776 | 0.75 | CA12 (0.69) | CA12CA9ELANECA2CA1 | |
| SCHEMBL30834902 | 0.75 | CA12 (1.00) | CA12CA9ELANECA2CA1 | |
| SCHEMBL1101896 | 0.75 | CA12 (1.00) | CA12CA9ELANECA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730142-B1 | NOVEL KETOAMIDES WITH CYCLIC P4'S AS INHIBITORS OF NS3 SERINE PROTEASE OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2011-06-29 | — | — | EP | disclosed |
| US-7619094-B2 | Ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | SCHERING CORPORATION (US) | 2009-11-17 | — | — | US | disclosed |
| US-20070093430-A1 | Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | MERCK SHARP & DOHME CORP. | 2007-04-26 | — | — | US | disclosed |
| US-7173057-B2 | Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus | SCHERING CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
| WO-2005085242-A1 | NOVEL KETOAMIDES WITH CYCLIC P4'S AS INHIBITORS OF NS3 SERINE PROTEASE OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093430-A1 | Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | PREP, PRSS1, P4HB | CA12 1583/4885CA9 2191/4885ELANE 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.